Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

Media formats available:

Improved health status with SGLT2-inhibitor in HFrEF
Improved health status with SGLT2-inhibitor in HFrEF
AHA 2019
Improved health status with SGLT2-inhibitor in HFrEF
- Prof. Mikhail Kosiborod
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
AHA 2019
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
AHA 2019
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
- Prof. Donald Lloyd-Jones
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
AHA 2019
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
- Prof. Lynne Stevenson

PACE-CME